Sputum matrix metalloproteinase-9: Tissue inhibitor of metalloproteinase-1 ratio in acute asthma

Background: The ratio of matrix metalloproteinase-9 (MMP-9) and its inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1) map be a marker of the balance between airway tissue destruction and repair. TIMP-1 may potentially contribute to the pathogenesis of increased submucosal extracellular matrix deposition in asthma. Objective: Our purpose was to assess the variation in sputum MMP-9 and TIMP-1 during acute asthma, Methods: We evaluated the MMP-9 and TIMP-1 balance in sputa of 16 asthmatic patients admitted with spontaneous exacerbation, conducting measurement before (day 1) and after methylprednisolone infusion therapy (days 2, 3, 5, and 7), and on remission days. Results: Peak expiratory flow and eosinophilic cationic protein levels were significantly (P < .05) improved within 7 days in all patients. Sputum MMP-9 revels on day 2 tended to be lower than on day 1, but not significantly Zymography revealed that the main enzyme was identified immunologically as MMP-9, and gelatinase activity on day I had a tendency to decrease for the following 7 days. The TIMP-1 levels gradually increased until day 5, were significantly (P < .05) high on day 5, and decreased on day 7. The MMP-9/TIMP-1 molar ratios were significantly (P < .05) decreased on days 2, 3, 5, and 7 compared with day 1. Sputum levels of MMP-9 and TIMP-1 and the MMP-9/TIMP-1 molar ratios on day 1 were significantly higher (P < .02) than those on remission days. Conclusions: An imbalance between MMP-9 and TIMP-1 was present in acute asthma, with an excess of MMP-9 resulting in a high ratio of MMP-9/TIMP-1 before treatment, and over time with glucocorticosteroid the TIMP-1 levels rose, dropping the ratio of MMP-9/TIMP-1. It was suggested that overproduction of MMP-9 and TIMP-1 after asthma exacerbation might contribute significantly to airway tissue remodeling and that TIMP-1 production in acute asthma might not be suppressed by glucocorticosteroid.